ADARx reports Q3 2026 results, Fast Track for onvuzosiran, three agazisiran trials ongoing
The company said cash and short-term investments reached $901.0 million as of September 30, 2026, which it expects to fund operations into 2030.
ADARx Pharmaceuticals reported third-quarter 2026 results on November 12, 2026, alongside updates on its siRNA pipeline. ADARx continued to advance three Phase 2 clinical trials for agazisiran, ongoing in renal diseases including IgA nephropathy, complement 3 glomerulopathy and immune complex membranoproliferative glomerulonephritis; in paroxysmal nocturnal hemoglobinuria; and in geographic atrophy secondary to age-related macular degeneration, to support its potential as what the company calls a pipeline-in-a-product opportunity.1 The company intends to explore additional dosing regimens in its Phase 2 IgAN and PNH trials.1
On the regulatory front, the FDA granted Fast Track designation in August 2026 to onvuzosiran for prophylaxis to prevent attacks of hereditary angioedema.1 Onvuzosiran is being evaluated in the Phase 3 STOP-HAE trial, registered as NCT06960213.1
For its Factor XI program, ADX-626, Phase 2 planning is underway for secondary stroke prevention and for exploratory studies in stroke prevention in patients with atrial fibrillation.1 The company decided not to evaluate higher doses beyond the third dose cohort, 400 mg, in the ongoing Phase 1 trial, and plans to test higher doses in the planned Phase 2 study instead.1
Anticipated milestones include mid-2027 nine-month UPCR reduction data and second-half 2027 one-year eGFR stabilization data for agazisiran in IgAN, second-half 2027 data in C3G and PNH, Phase 3 STOP-HAE topline data for onvuzosiran by year-end 2027, Phase 2a/b initiation for ADX-626 in SSP in 2027, and Phase 1 initiations for ADX-077 in obesity and ADX-199 in 2027 or early 2028, according to the release.
On financing, ADARx closed its IPO of 30,187,500 shares, including 3,937,500 shares sold October 1, 2026 under the underwriters' overallotment option, at $17.00 per share, generating $513.2 million in gross IPO proceeds plus $89.3 million from a concurrent private placement of 5,255,542 shares with AbbVie, for aggregate gross proceeds of about $602.5 million; its common stock began trading on Nasdaq under "ADRX" on September 25, 2026.1
As of September 30, 2026, ADARx had cash, cash equivalents and short-term investments of $901.0 million.1 The company said this amount, together with subsequent overallotment proceeds, is expected to fund operating expenses and capital expenditures into 2030.1 Net loss for the quarter was $28.1 million, compared with $17.9 million in the same period of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.